On July 3, Bloomberg News reported that AstraZeneca (NASDAQ: AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing ...

AstraZeneca, Daiichi Sankyo obtain FDA nod for Datroway Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot wants to move the drugmaker’s stock listing to the US, the Times reported, in what would be another sign of the UK’s waning status as ...

Datroway is the first and only TROP2-directed antibody-drug conjugate (ADC) approved in the U.S. for lung cancer. The drug is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

The aim is to find and treat lung cancers early, before they grow and spread, to improve the chance of survival. Here’s what’s involved.

AstraZeneca has started the process to improve its cancer treatment capabilities with an addition to its campus in southwest Frederick.

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in ...

FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.